ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage - PubMed
6 hours ago
- #HER3-DXd
- #ATR inhibition
- #breast cancer
- HER3 overexpression occurs in up to 70% of HR+ breast cancers, associated with poor prognosis and endocrine therapy resistance.
- HER3-DXd combined with an ATR inhibitor enhances DNA damage, apoptosis, and tumor growth inhibition in both parental and tamoxifen-resistant HER3+/HR+ breast cancer cells.
- Clinical database analyses show high HER3 expression and that high ATR, CHEK1, and TOP1 gene expression correlate with poor prognosis in HR+ breast cancer.